Company Filing History:
Years Active: 2021
Title: Stefanie Straub: Innovator in Pharmaceutical Formulations
Introduction
Stefanie Straub is a notable inventor based in Bad Vilbel, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications for pain management. Her innovative work has the potential to improve treatment options for patients, especially in pediatric care.
Latest Patents
Stefanie holds a patent for a stable formulation for parenteral administration of tapentadol. This invention relates to an aqueous pharmaceutical composition that includes tapentadol or a physiologically acceptable salt thereof. The concentration of tapentadol in the composition ranges from 0.10 to 8.00 mg/mL, based on the weight of the tapentadol free base and the total volume of the composition. The pH value of the composition is buffered and maintained within the range of 4.0 to 6.0. Additionally, the invention encompasses a container that holds the pharmaceutical composition and a process for its preparation. A kit containing the invention in suitable packaging is also part of her patent. This pharmaceutical composition is particularly beneficial for treating acute pain, especially in pediatric patients.
Career Highlights
Stefanie is associated with Grunenthal GmbH, a company known for its focus on pain management solutions. Her work at Grunenthal has allowed her to contribute to the development of innovative pharmaceutical products that address critical healthcare needs.
Collaborations
Stefanie has collaborated with notable colleagues, including Marc Schiller and Carlos Van Hemelrijck. These partnerships have fostered a collaborative environment that enhances the innovation process within the pharmaceutical industry.
Conclusion
Stefanie Straub's contributions to pharmaceutical formulations exemplify the impact of innovation in healthcare. Her patent for a stable tapentadol formulation showcases her commitment to improving pain management, particularly for vulnerable patient populations.